This team proposes the protein called integrin αvβ6 as a target for peptide receptor radionuclide therapy (PRRT), an approved molecular targeted therapy used to treat neuroendocrine tumors. αvβ6 is significantly increased in pancreatic cancer, especially in metastasis. The scientists have developed a radiolabeled αvβ6-targeting peptide that they have successfully used to image pancreatic cancer metastases. In this study they are developing and testing a similar peptide, 177Lu-αvβ6-BP, to evaluate the safety and efficacy of that treatment in patients with locally advanced, or metastatic pancreatic cancer, and determine the most effective dose to be studied in a Phase II clinical trial.
See Team Page